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Sex Med 2Introduction: Erectile dysfunction (ED) is prevalent in men with metabolic syndrome (MetS); therefore, it is
important to characterize ED treatments in this population.
Aims: To investigate the safety and effectiveness of vardenaﬁl in men with ED and MetS in a clinical setting.
Methods: REVITALISE is an international, prospective, single-arm, observational study in men with ED and
MetS newly prescribed vardenaﬁl. Vardenaﬁl was prescribed at the discretion of the treating physician in line
with the marketing authorization. Treatment effectiveness (International Index of Erectile Function [IIEF]) and
health-related quality of life (Aging Males’ Symptoms Scale) were assessed at treatment initiation, at an optional
dose adjustment visit after approximately 4 weeks, and at the end of the observation period (approximately 12
weeks).
Main Outcome Measures: The primary outcome was an intraindividual improvement in erectile function
(EF), deﬁned as an increase of at least four points in the EF domain of the IIEF. Secondary outcomes included
assessing normal EF (IIEF-EF score  26), mild ED (IIEF-EF score ¼ 22e25), and health-related quality of life.
Treatment-emergent adverse events were monitored.
Results: In the intent-to-treat population (n ¼ 1,832, mean age ¼ 54.0 years, mean body mass index ¼
31.82 kg/m2, Asian 36.8%, white 49.9%, 20.4% with severe ED, 75.6% with mild or moderate ED, 4.0%
without ED), 82.4% reported an increase of at least four points in IIEF-EF score. Median IIEF-EF score
increased from 15.0 (baseline) to 25.0 at 12 weeks (P < .0001). After treatment, 45.4% and 29.4% (intent-to-
treat population) had normal EF and mild ED, respectively. Improvements in the sexual, psychological, and
somatic subscales of the Aging Males’ Symptoms Scale were found (P < .0001). Treatment-emergent adverse
events were reported by 7.19% of patients; there were no serious adverse events related to vardenaﬁl.
Conclusion: In a clinical setting, men with ED and MetS treated with vardenaﬁl reported improvements in EF
and health-related quality of life; and the safety proﬁle of vardenaﬁl was acceptable. REVITALISE demonstrates
that vardenaﬁl represents a good treatment option for men with ED and MetS.
Sex Med 2016;4:e135ee144. Copyright  2016, The Authors. Published by Elsevier Inc. on behalf of the Inter-
national Society for Sexual Medicine. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
Key Words: Erectile Dysfunction; Metabolic Syndrome; Phosphodiesterase Type 5 Inhibitor; VardenaﬁlINTRODUCTION
Erectile dysfunction (ED) is estimated to affect more than 150
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016;4:e135ee144men with metabolic syndrome (MetS) and related conditions
such as hypertension and diabetes compared with the general
population.1-6 A recent analysis found that approximately 40%
of patients with ED also have MetS, and ED is almost twice as
prevalent in patients with MetS compared with those without it.7
Furthermore, evidence suggests that the relative risk and severity
of ED increase as the number of MetS components increases.1,2
Owing to the large proportion of patients with ED and MetS, it
is important that the safety and effectiveness of ED treatments
are fully evaluated in this population.
Phosphodiesterase 5 (PDE5) inhibitors, such as vardenaﬁl, are
currently the ﬁrst-line pharmacologic treatment for ED.8-10e135
e136 Shabsigh and MatternSeveral studies have demonstrated that vardenaﬁl is a safe and
effective treatment for patients with ED.11-17 It also has been
found highly effective in men with ED and underlying comor-
bidities, such as diabetes, hypertension, and dyslipidemia.18-23
The ﬁrst prospective study to examine vardenaﬁl use in men
with MetS was a small-scale 12-week placebo-controlled study of
145 men with ED and MetS in Germany.24 It demonstrated that
vardenaﬁl was well tolerated and improved erectile function (EF)
compared with placebo24; however, further evidence form larger-
scale studies is required. This non-interventional observational
study is the ﬁrst large-scale international trial to investigate
prospectively the effectiveness of vardenaﬁl in patients with ED
and MetS.AIM
The TheRapeutic Effectiveness of VardenafIl in ED patients
with the meTAboLIc SyndromE in daily clinical practice
(REVITALISE) study was designed to investigate the effective-
ness and safety of newly prescribed vardenaﬁl in men with ED
and MetS in the clinical setting.METHODS
Study Design
In this international, multicenter, prospective, single-arm,
non-interventional, observational study (NCT01106118),
patients were recruited from 171 study centers in 10 countries
(Egypt, Israel, Kazakhstan, Kyrgyzstan, Republic of Korea,
Lebanon, Russia, Saudi Arabia, Singapore, and Ukraine) from
January 2010 to October 2012. Where required, according to
local laws and regulations, independent ethics committee or
institutional review board approval was gained; and written
informed consent from patients was obtained when they agreed
to participate.Inclusion and Exclusion Criteria
Patients with a diagnosis of ED and documented MetS who
were newly prescribed vardenaﬁl without prior use of any PDE5
inhibitor within 1 month of study entry were eligible for
inclusion. The International Diabetes Federation (IDF) criteria
for MetS1 were strongly recommended: a waist circumference of
at least 94 cm in European, sub-Saharan African, Eastern
Mediterranean, and Middle East (Arab) populations; at least
90 cm in ethnic South Asians, Chinese, and ethnic South and
Central Americans; and at least 82 cm in the Japanese popula-
tion; and at least two of the following criteria: triglyceride level at
least 150 mg/dL or speciﬁc treatment for this abnormality, high-
density lipoprotein cholesterol level lower than 40 mg/dL or
speciﬁc treatment for this abnormality, systolic blood pressure
(BP) at least 130 mmHg and/or diastolic BP of at least
85 mmHg or previously diagnosed hypertension, and fasting
plasma glucose level at least 100 mg/dL or previously diagnosed
type 2 diabetes.The contraindications and warnings of the Summary of
Product Characteristics25 deﬁned the exclusion criteria for the
study.Study Medication
Vardenaﬁl was prescribed in accordance with the marketing
authorization and paid for according to standard local practice.
The treatment decision was within current practice and no
additional diagnostic or monitoring was required for participa-
tion in the study. The duration and dose (5-, 10-, or 20-mg
tablets) of treatment were determined by the physician.Study Protocol
Effectiveness was measured using the International Index of
Erectile Function (IIEF), the internationally recognized gold
standard for assessing ED treatments.26-28 The Aging Males’
Symptoms (AMS) scale29 (Supplementary File 1) was used to
assess health-related quality of life (HRQoL); however, comple-
tion of the questionnaire was optional. With the exception of the
Russian translation of the AMS scale, the translations of the
questionnaire were produced in accordance with the methodo-
logic recommendations for linguistic and cultural adaption of
HRQoL measurements.29-31
Patients were followed for approximately 12 weeks, with
observations recorded at two to three consecutive visits: at
vardenaﬁl initiation, at an optional visit after approximately
4 weeks (if dose adjustment was required according to the clinical
response of the patient), and at the end of the 12-week obser-
vation period.
At the initial enrollment visit, the patients’ demographic
information, components of MetS, ED history, prescribed
vardenaﬁl dose, and concomitant conditions and medications
were recorded. ED etiology was classiﬁed by the treating physi-
cian based on the physician’s assessment of the patient and the
patient’s medical history. The IIEF26 and AMS scale29 (optional)
questionnaires also were completed.
At the optional dose adjustment visit, the IIEF questionnaire
was completed and the physician recorded the prescribed
vardenaﬁl dose, the number of tablets taken since the ﬁrst visit
(as reported by the patient), changes in concomitant medication,
and adverse events (AEs). At the ﬁnal visit, at the end of the
study or at discontinuation of therapy (whichever was sooner),
the IIEF and AMS scale (optional) questionnaires and global
assessment question were completed. The physician recorded the
prescribed vardenaﬁl dose, the number of tablets taken since the
last visit (as reported by the patient), concomitant medication,
and AEs. Patients could discontinue the study at any time; if
discontinuation occurred before the 12-week assessment, then it
was considered the ﬁnal visit. Patients who withdrew from the
study were not replaced and were not permitted to re-enter.
AEs were recorded at each visit and coded using the Medical
Dictionary for Regulatory Activities version 15.1. An AE wasSex Med 2016;4:e135ee144
Subjects enrolled
n=2316
244 patients excluded
4, did not take any study medication
15, no post-baseline documentation
225, substantiated fraud
240 patients excludeda
63, final visit was not within 4–26 weeks of initial prescription
74, did not have erectile dysfunction
27, did not have metabolic syndrome
179, used a PDE5 inhibitor within 1 month of initial prescription
240 patients excluded
No valid efficacy data
Safety population
n=2072
ITT population
n=1832
PP population
n=1592
Figure 1. Study populations. aMultiple responses were possible. ITT ¼ intent-to-treat; PDE5 ¼ phosphodiesterase type 5;
PP ¼ per-protocol.
REVITALISE e137considered a treatment-emergent AE (TEAE) if it began from the
date of the ﬁrst prescription to 7 days after the ﬁnal study visit.Patient Populations
A patient was included in the safety analysis if at least one dose
of study medication was taken or was considered taken in cases in
which any post-baseline data were documented but information
on study medication intake was missing. Patients valid for safety
analysis, that is, who had valid efﬁcacy data at their ﬁrst dose of
vardenaﬁl and at either dose adjustment or ﬁnal visit, were
included in the intent-to-treat (ITT) population. Valid efﬁcacy
data were deﬁned as a valid score (0, 1, 2, 3, 4, or 5) for all six
items of the IIEF-EF. Patients valid for ITT were excluded from
the per-protocol (PP) population if they were younger than 18
years, had no ED (IIEF-EF score  26 at initial visit), or did not
have MetS as deﬁned by the IDF, World Health Organization,32
the European Group for the Study of Insulin Resistance,33 the
National Cholesterol Education Program Adult Treatment Panel
III (NCEP ATP III),34 or IDF and NCEP ATP III consensus.35MAIN OUTCOME MEASURES
The primary objective was to determine a clinically relevant,
intraindividual improvement in EF, deﬁned as an increase of at
least four points in IIEF-EF score after approximately 12 weeks
of treatment.
The secondary objectives were to determine an increase of at
least ﬁve points in IIEF-EF score and to assess normal EF (IIEF-EFSex Med 2016;4:e135ee144score  26 points), mild ED (IIEF-EF¼ 22e25 points), and the
effect of vardenaﬁl on HRQoL using the AMS Scale after
approximately 12 weeks of treatment. Subgroup analyses of
changes in IIEF-EF were performed for race, body mass index
(BMI), age, and alcohol consumption.
Safety was assessed according to TEAEs.Statistical Analyses
Approximately 2,000 patients were considered sufﬁcient to
detect a percentage of patients with at least four-point
improvement of 72% within a 95% CI ± 2.5% (primary
outcome).
Descriptive analysis of the data was performed using summary
statistics for categorical and quantitative (continuous) data.
Continuous data were described by the number of non-missing
values, median, mean, SD, minimum, and maximum and 1, 5,
25, 75, 95, and 99 percentile quantiles. Frequency tables were
generated for categorical data and missing was included as a
category.
Efﬁcacy end-point analyses were performed for the ITT and
PP populations. The change from baseline IIEF-EF score was
tabulated by visit and for the ﬁnal visit; the last observation
carried forward was used for the primary end point only. The
increase in IIEF-EF score was analyzed non-parametrically using
the Wilcoxon signed rank test (one-sided). The Fisher exact test
was used to compare changes in categorized IIEF-EF domain
scores and overall satisfaction. The AMS scores were analyzed
descriptively by summary statistics for absolute scores and
Table 1. Study population demographics and clinical characteristics
of erectile dysfunction
Safety
population
(n ¼ 2,072)
ITT population
(n ¼ 1,832)
Age, y
Mean (SD) 53.6 (9.97) 54.0 (9.87)
Range 22e85 22e85
Weight, kg
Mean (SD) 95.71 (16.98) 95.05 (16.63)
Range 53.5e220.0 53.5e220.0
BMI, kg/m2
Mean (SD) 32.03 (5.44) 31.82 (5.35)
Range 19.5e70.8 19.5e70.8
Race, n (%)
Asian 714 (34.5) 674 (36.8)
White 1,040 (50.2) 915 (49.9)
Black 60 (2.9) 28 (1.5)
Other 144 (6.9) 120 (6.6)
No data 114 (5.5) 95 (5.2)
Nicotine consumption, n (%)
Never 700 (33.8)
Former smoker 420 (20.3)
Current smoker 853 (41.2)
No data 99 (4.8)
Alcohol consumption, n (%)
Abstinent 809 (39.0)
Light 722 (34.8)
Moderate 366 (17.7)
Heavy 52 (2.5)
No data 123 (5.9)
Physical exercise, n (%)
None 1,065 (51.4)
1 h/wk 360 (17.4)
2 h/wk 258 (12.5)
3 h/wk 160 (7.7)
4 h/wk 140 (6.8)
No data 89 (4.3)
ED duration, n (%)
<6 mo 392 (18.9)
6e12 mo 732 (35.3)
1e3 y 566 (27.3)
>3 y 374 (18.1)
No data 8 (0.4)
ED etiology, n (%)
Organic 607 (29.3)
Psychogenic 166 (8.0)
Mixed 1,005 (48.5)
No data 294 (14.2)
Previous ED treatment, n (%)
No treatment 1,238 (59.7)
Sildenaﬁl 406 (19.6)
Tadalaﬁl 199 (9.6)
Vardenaﬁl 16 (0.8)
(continued)
Table 1. Continued
Safety
population
(n ¼ 2,072)
ITT population
(n ¼ 1,832)
Other 133 (6.4)
No data 80 (3.9)
Concomitant diseases, n (%)*
Arteriosclerosis 151 (7.3)
Benign prostatic hyperplasia 413 (19.9)
Coronary heart disease 70 (3.4)
Depression 76 (3.7)
Myocardial infarction 62 (3.0)
Concomitant cardiovascular
medications, n (%)
930 (44.9)
Agents acting on
renin-angiotensin system
392 (18.9)
Antihypertensives 7 (0.3)
b-Blockers 292 (14.1)
Calcium channel blockers 139 (6.7)
Cardiac therapy 27 (1.3)
Diuretics 43 (2.1)
Lipid-modifying agents 508 (24.5)
Peripheral vasodilators 3 (0.1)
Vaso-protective agents 10 (0.5)
BMI ¼ body mass index; ED ¼ erectile dysfunction; ITT ¼ intent-to-treat.
*By prespeciﬁed term; reported by at least 3% of the safety population.
e138 Shabsigh and Matternchanges from baseline; the Wilcoxon signed rank test (one-sided)
was used to analyze improvement in total AMS score.
Data management and statistical analyses were performed
using SAS 9.2 (SAS Institute, Cary, NC, USA).RESULTS
Study Population
Of 2,316 patients enrolled in the study, 2,072 patients were
included in the safety population; of these, 1,832 had valid efﬁ-
cacy data and were included in the ITT population and 1,592
were included in the PP population (Figure 1). In the safety
population, the mean age was 53.6 years (SD ¼ 9.97), mean
weight was 95.71 kg (SD ¼ 16.98), and mean BMI was
32.03 kg/m2 (SD ¼ 5.44; Table 1). At the initial visit, 374
(20.4%) patients had severe ED, 701 (38.3%) had moderate ED,
494 (27.0%) had mild to moderate ED, 190 (10.4%) had mild
ED, and 73 (4.0%) had no ED (ITT population). In total, 1,005
patients (48.5%) had a mixed organic and psychogenic ED
etiology, 1,672 patients (80.7%) had ED for at least 6 months,
59.7% had not previously received any treatment for ED, and
fewer than 1% had previously taken vardenaﬁl (Table 1). The
IDF criteria were used to diagnose MetS for 1,123 patients
(54.2%) in the safety population; other deﬁnitions were the
World Health Organization (715 patients, 34.5%), the European
Group for the Study of Insulin Resistance (17 patients, 0.8%),Sex Med 2016;4:e135ee144
Table 2. Patient characteristics related to metabolic syndrome
(safety population, n ¼ 2,072)
Characteristic n Mean (SD) Range
Waist circumference, cm
Asian 702 98.02 (11.17) 78.7e180.0
Non-Asian 1,214 106.93 (11.89) 79.0e180.0
Unknown ethnicity 107 104.31 (10.70) 90.0e133.0
Total cholesterol, mg/dL 1,051 221.44 (50.67) 89.00e479.51
LDL cholesterol, mg/dL 958 136.45 (42.90) 10.82e299.00
HDL cholesterol, mg/dL 1,058 46.38 (28.98) 10.44e371.23
Triglycerides, mg/dL 1,125 216.33 (113.93) 44.27e1,416.64
HbA1c, % 603 7.48 (1.59) 3.57e13.00
Testosterone, nmol/L 923 13.38 (8.56) 0.13e61.37
HbA1c ¼ glycated hemoglobin; HDL ¼ high-density lipoprotein; LDL¼ low-
density lipoprotein.
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Figure 2. Analysis of IIEF domain scores. Panel A shows median
IIEF domain scores for the ITT population at the initial and ﬁnal
visits. Panel B shows categorized IIEF-EF domain scores for the
ITT population at the initial and ﬁnal visits. *P < .0001. Lines
indicate the maximum possible score achievable for each domain.
ED ¼ erectile dysfunction; IIEF ¼ International Index of Erectile
Function; IIEF-EF ¼ International Index of Erectile Functioneerectile
function domain; ITT ¼ intent-to-treat; LOCF ¼ last observation
carried forward.
REVITALISE e139the NCEP ATP III (22 patients, 1.1%), and a consensus of the
IDF and NCEP ATP III (225 patients, 10.9%). In the safety
population, 31.3% had triglyceride levels of at least 150 mg/dL or
were receiving treatment for dyslipidemia, 26.7% had high-
density lipoprotein cholesterol levels lower than 40 mg/dL or
were receiving treatment for dyslipidemia, 47.2% had systolic BP
of at least 130 mmHg or diastolic BP of at least 85 mmHg or were
receiving antihypertensive treatment, and 33.8% had fasting
blood glucose levels of at least 100 mg/dL or were diagnosed with
or treated for type 2 diabetes (Table 2).
Most patients reported a concomitant disease; 519 patients
(25.0%) reported one, 456 (22.0%) reported two, 255 (12.3%)
reported three, and 539 (26.0%) reported none (Table 1,
Supplementary Table 1). Concomitant medications were reported
by 1,431 patients (69.1%), with drugs acting on the cardiovascular
system (930 patients, 44.9%) and drugs used in diabetes (632 pa-
tients, 30.5%) being the most common (Table 1, Supplementary
Table 1).Efﬁcacy
The primary objective of a clinically relevant improvement in
IIEF-EF score of at least four points was achieved by 82.4% of
the ITT population and 85.5% of the PP population. Another
7.8% of patients recorded a one- to three-point increase; 4.4%
and 5.5% reported no change and a decrease in score, respec-
tively (ITT). The median IIEF-EF score increased from 15.0 at
the initial visit to 25.0 at the ﬁnal visit (P < .0001; Figure 2A).
There were no differences in domain scores between the ITT and
PP populations.
The secondary outcome, improvement of IIEF-EF score by at
least ﬁve points, was achieved by 78.9% of the ITT population.
At the end of the study, 45.4% and 29.4% of the ITT population
had normal EF (IIEF-EF score  26) and mild ED (IIEF-EF ¼
22e25), respectively (Figure 2B). The percentage of patients
(44.4%) with an improvement in IIEF-EF score from lower than
26 to at least 26 was signiﬁcantly larger (P ¼ .0102) than theSex Med 2016;4:e135ee144percentage of patients (30.1%) reporting a decrease in IIEF-EF
score of at least 26 to lower than 26.
Subgroup analyses demonstrated that fewer patients of Asian
origin (66.3%) reported an IIEF-EF score improvement of at
least ﬁve points compared with the complete ITT population
(78.9%). This ﬁnding was particularly evident in patients from
the Republic of Korea (57.6%) and Singapore (54.5%). Fewer
Asian patients with a lower BMI (50.0% with BMI < 23 kg/m2
and 58.7% with BMI ¼ 23e25 kg/m2) reported an IIEF-EF
score improvement of at least ﬁve points compared with Asian
patients with a higher BMI (76.5% with BMI > 30 kg/m2).
Stratiﬁcation of patients according to age showed that fewer
patients older than 70 years had at least a ﬁve-point improvement
in IIEF-EF score compared with the complete ITT population
(65.1% vs 78.9%, respectively). Heavy alcohol consumption also
had a negative effect on ED improvement, with 65.6% of pa-
tients in this group reporting at least a ﬁve-point improvement in
IIEF-EF score.
For all IIEF domains, a mean improvement of at least two
points was achieved (Figure 2A). After treatment, the percentage
of patients rating their conﬁdence of getting and maintaining an
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Figure 3. Percentage of ITT population (n ¼ 1,832) achieving
Aging Males’ Symptoms total score in each category. The total
score for all 17 questions was categorized according to the degree
of symptom severity. ITT ¼ intent-to-treat.
e140 Shabsigh and Matternerection as high or very high increased from 5.3% to 44.9% and
1.1% to 17.4%, respectively. Furthermore, the percentage of
patients reporting satisfactory sexual intercourse most times or
almost always or always increased from 12.1% or 5.8% at the
initial visit to 37.4% or 39.0%, respectively. Within the orgasmic
function domain, at the initial visit, 35.3% of patients reported
having the sensation of orgasm most times or almost always or
always when they had sexual stimulation or intercourse; at the
ﬁnal visit, this increased to 78.7%. Contributing to the overall
satisfaction domain, 30.9% of patients were very satisﬁed and
42.6% were moderately satisﬁed with their sex life at the ﬁnal visit
compared with 2.2% (P ¼ .0388) and 13.5% (P < .001),
respectively, at the initial visit.
The optional AMS questionnaire was completed by 1,159
patients at their initial visit and 1,198 patients at their ﬁnal visit.
The median total AMS score improved from 37.0 (moderate
symptoms) to 24.0 (mild symptoms; Figure 3). After treatment,
more than 40% of patients were classiﬁed as having no symp-
toms. Improvement was observed in all subscales, with decreases
in the median from 13.0 to 8.0 on the sexual subscale, 10.0 to
6.0 on the psychological subscale, and 14.0 to 10.0 on the
somatic subscale (P < .0001 for all comparisons).Safety
In total, 185 TEAEs were reported, with 149 (7.19%) patients
reporting at least one TEAE (Table 3). Drug-related AEs were
reported by 107 patients (5.16%); the most common were
headache (51 patients, 2.46%) and ﬂushing and facial ﬂushing
(1e2%). Two patients had serious AEs; one died of leukemia
and one had a non-fatal myocardial infarction, neither of which
was related to vardenaﬁl.Vardenaﬁl Treatment
Throughout the course of the study, most patients were
prescribed vardenaﬁl 20 mg (Table 4). The optional dose-
adjustment visit was attended by 988 patients (47.7%); of
these, 635 patients (64.3%) were prescribed vardenaﬁl 20 mg.The number of tablets taken during the course of the study
ranged from 1 to 133.
After the ﬁnal study visit, more than 80% of patients planned
to continue treatment. The main reasons for discontinuation
were insufﬁcient efﬁcacy (115 of 392 patients), price (108 of 392
patients), and ED cured or improved (79 of 392 patients).DISCUSSION
This large, observational study demonstrates that in a clinical
setting, vardenaﬁl improves EF in patients with ED and MetS.
After a treatment period of approximately 12 weeks, based on
IIEF results, more than 80% of patients reported an improve-
ment in EF and 45% of patients had normal EF. Patients
receiving vardenaﬁl had an improvement in all domains of the
IIEF questionnaire, highlighting the beneﬁcial effects of varde-
naﬁl not only on EF but also on intercourse satisfaction,
orgasmic function, sexual desire, and overall satisfaction. These
results support the ﬁndings of previous clinical trials that have
reported the efﬁcacy of vardenaﬁl in patients with ED and
cardiovascular or metabolic conditions.18-23
A strength of this study is that a large number of patients was
recruited from a wide demographic base for age (range ¼ 22e85
years), race (34.5% Asian and 50.2% white), and BMI (range ¼
19.5e70.8 kg/m2). This demographic base enabled efﬁcacy to be
compared between subgroups. Vardenaﬁl was less effective in pa-
tients of Asian ethnicity, particularly those with a lower BMI
(18.5e23 kg/m2). There is conﬂicting evidence regarding the
effectiveness of PDE5 inhibitors in Caucasians and Asians. In
agreement with this study, a recent meta-analysis found that, in a
pooled analysis of PDE5 inhibitors, treatment wasmore effective in
Caucasians compared with Asians.36 However, a smaller (N¼ 334
patients; 264 vardenaﬁl, 70 placebo) study investigating vardenaﬁl
efﬁcacy in Asian men reported a signiﬁcant increase in IIEF-EF
score, which was similar to that seen in previous studies in
Caucasians.37 Direct comparisons between studies are difﬁcult to
make owing to differences in protocols; thus, further investigation is
warranted to explore these potential ethnic differences and their
causes. The lower effectiveness of vardenaﬁl in Asian patients with a
lower BMI also requires further investigation; this ﬁnding might
need to be considered when physicians prescribe treatment for this
speciﬁc subgroup of patients.
The subgroup analyses also demonstrated that vardenaﬁl was
less effective in improving EF in men older than 70 years. This is
an important issue because the prevalence and severity of ED
increase with age38 owing to multiple pathophysiologic changes
in erectile mechanisms, such as a decrease in endogenous nitric
oxide production.39 It has been proposed that combining
testosterone supplementation with a PDE5 inhibitor might
improve its efﬁcacy by increasing nitric oxide bioavailability and
helping to maintain the health of erectile tissue and surrounding
nerves.39,40 Further studies to determine the beneﬁt of using a
combination treatment strategy in elderly men are warranted.Sex Med 2016;4:e135ee144
Table 3. Treatment-emergent adverse events (safety population,
n ¼ 2,072)
MedDRA SOC Preferred term
Patients
reporting
event, n (%)
Any body system Patients with AEs 149 (7.19)
Patients without AEs 1,885 (90.97)
Missing 38 (1.83)
Cardiac disorders All 5 (0.24)
Heart pounding 1 (0.05)
Myocardial infarction 1 (0.05)
Palpitation 2 (0.10)
Tachycardia 1 (0.05)
Eye disorders All 4 (0.19)
Ocular hyperemia 2 (0.10)
Red eye 1 (0.05)
Visual disturbance 1 (0.05)
Gastrointestinal
disorders
All 9 (0.43)
Abdominal discomfort 1 (0.05)
Dyspepsia 1 (0.05)
Gastritis 1 (0.05)
Nausea 6 (0.29)
General disorders and
administration site
conditions
All 1 (0.05)
Lack of drug effect 1 (0.05)
Infections and
infestations
All 1 (0.05)
Rhinitis 1 (0.05)
Investigations All 1 (0.05)
Heart rate high 1 (0.05)
Musculoskeletal and
connective tissue
disorders
All 8 (0.39)
Back pain 2 (0.10)
Bone pain 2 (0.10)
Low back pain 1 (0.05)
Muscle pain 1 (0.05)
Musculoskeletal pain 1 (0.05)
Myalgia 1 (0.05)
Neoplasms benign,
malignant, and
unspeciﬁed (including
cysts and polyps)
All 1 (0.05)
Leukemia 1 (0.05)
Nervous system
disorders
All 81 (3.91)
Dizziness 3 (0.14)
Drowsiness 1 (0.05)
Fainting 1 (0.05)
Headache 75 (3.62)
Sleepiness 3 (0.14)
Tremor 1 (0.05)
Psychiatric disorders All 3 (0.14)
(continued)
Table 3. Continued
MedDRA SOC Preferred term
Patients
reporting
event, n (%)
Anxiety 2 (0.10)
Insomnia 1 (0.05)
Respiratory, thoracic,
and mediastinal
disorders
All 12 (0.58)
Gasping 1 (0.05)
Nasal congestion 10 (0.48)
Nasal obstruction 1 (0.05)
Skin and subcutaneous
tissue disorders
All 7 (0.34)
Itching 1 (0.05)
Rash 2 (0.10)
Redness of face 1 (0.05)
Skin hyperemia 2 (0.10)
Skin warm 1 (0.05)
Vascular disorders All 36 (1.74)
Facial ﬂushing 3 (0.14)
Flushing 25 (1.21)
Flushing of face 2 (0.10)
Hot facial ﬂushes 1 (0.05)
Hypertensive crisis 4 (0.19)
Hypotension 1 (0.05)
No coding available 8 (0.39)
AEs ¼ adverse events; MedDRA SOC ¼ Medical Directory for Drug Reg-
ulatory Activities—System Organ Class.
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REVITALISE e141In patients who completed the AMS scale, an improvement in
HRQoL was reported. This improvement was not limited to the
sexual subscale but also was seen for the psychological and so-
matic subscales, highlighting the importance of EF in overall
HRQoL.
Vardenaﬁl was well tolerated with no serious TEAEs reported.
The low incidence and type of drug-related AEs were in
line with the vardenaﬁl product information25 and previous
studies.11,12,16,18,24
The main limitation of this study is that the follow-up period
was only 12 weeks; a longer follow-up with more scheduled visits
would have strengthened the data. Although completion of the
AMS scale was optional, a total score for the initial and ﬁnal visits
were provided for 63% and 65% of the ITT population,
respectively. AEs were recorded only at the follow-up visit and
therefore might have been under-reported. However, the inci-
dence of AEs reported here was similar to that observed in other
studies,11,12,16,18,24 suggesting that the reliability of the data has
not been adversely affected. In addition, owing to the observa-
tional nature of this study and to the lack of a control group, we
cannot rule out potential confounding; a further placebo-
controlled study is warranted. Although this study was non-
interventional, to date, it is the only study in which vardenaﬁl
Table 4. Prescribed dose of vardenaﬁl (safety population, n ¼
2,072)
Dose of
vardenaﬁl
Initial visit,
n (%)
Dose adjustment
visit, n (%)*
Final visit,
n (%)
5 mg 94 (4.5) 71 (7.2) 109 (5.3)
10 mg 616 (29.7) 256 (25.9) 471 (22.7)
10 and 20 mg 4 (0.2) 0 0
20 mg 1,339 (64.6) 635 (64.3) 1,242 (59.9)
Missing data 19 (0.9) 26 (2.6) 250 (12.1)
*Attended by 988 patients.
e142 Shabsigh and Matterninitiation in men with ED and MetS was observed in routine
clinical practice.
In summary, the REVITALISE study has demonstrated that,
in clinical practice, vardenaﬁl is effective and has an acceptable
safety proﬁle in men with ED and MetS.
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Supplementary Table 1. AMS Questionnaire
Which of the following symptoms apply to you at this time? Please, mark the appropriate box for each symptom. For symptoms that do
not apply, please mark “none”.
Symptoms: extremely
none mild moderate Severe severe
I I I I I
Score ¼ 1 2 3 4 5
1. Decline in your feeling of general well-being (general state of health, subjective feeling) , , , , ,
2. Joint pain and muscular ache (lower back pain, joint pain, pain in a limb, general back ache) , , , , ,
3. Excessive sweating (unexpected/sudden episodes of sweating, hot ﬂushes independent of strain) , , , , ,
4. Sleep problems (difﬁculty in falling asleep, difﬁculty in sleeping through, waking up early and
feeling tired, poor sleep, sleeplessness)
, , , , ,
5. Increased need for sleep, often feeling tired , , , , ,
6. Irritability (feeling aggressive, easily upset about little things, moody) , , , , ,
7. Nervousness (inner tension, restlessness, feeling ﬁdgety) , , , , ,
8. Anxiety (feeling panicky) , , , , ,
9. Physical exhaustion / lacking vitality (general decrease in performance, reduced activity, lacking
interest in leisure activities, feeling of getting less done, of achieving less, of having to force oneself
to undertake activities)
, , , , ,
10. Decrease in muscular strength (feeling of weakness) , , , , ,
11. Depressive mood (feeling down, sad, on the verge of tears, lack of drive, mood swings, feeling
nothing is of any use)
, , , , ,
12. Feeling that you have passed your peak , , , , ,
13. Feeling burnt out, having hit rock-bottom , , , , ,
14. Decrease in beard growth , , , , ,
15. Decrease in ability/frequency to perform sexually , , , , ,
16. Decrease in the number of morning erections , , , , ,
17. Decrease in sexual desire/libido (lacking pleasure in sex, lacking desire for sexual intercourse) , , , , ,
Have you got any other major symptoms? Yes , No ,
If Yes, please describe:eeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeee
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